CN112190601A - 一种改善记忆力、延缓衰老、抗氧化的片剂及其制备方法 - Google Patents
一种改善记忆力、延缓衰老、抗氧化的片剂及其制备方法 Download PDFInfo
- Publication number
- CN112190601A CN112190601A CN202010991627.3A CN202010991627A CN112190601A CN 112190601 A CN112190601 A CN 112190601A CN 202010991627 A CN202010991627 A CN 202010991627A CN 112190601 A CN112190601 A CN 112190601A
- Authority
- CN
- China
- Prior art keywords
- tablet
- portions
- resisting oxidation
- delaying
- nmn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003647 oxidation Effects 0.000 title claims abstract description 26
- 238000007254 oxidation reaction Methods 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000032683 aging Effects 0.000 title claims description 23
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 24
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000011701 zinc Substances 0.000 claims abstract description 21
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 21
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011248 coating agent Substances 0.000 claims abstract description 18
- 238000000576 coating method Methods 0.000 claims abstract description 18
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 18
- 239000011669 selenium Substances 0.000 claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 12
- 229920002472 Starch Polymers 0.000 claims abstract description 12
- 239000008101 lactose Substances 0.000 claims abstract description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 12
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 12
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 12
- 239000008107 starch Substances 0.000 claims abstract description 12
- 235000019698 starch Nutrition 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 10
- 230000009758 senescence Effects 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims description 12
- 238000004806 packaging method and process Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 230000003712 anti-aging effect Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000003993 interaction Effects 0.000 abstract description 2
- 230000009044 synergistic interaction Effects 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 32
- 239000000047 product Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 230000006870 function Effects 0.000 description 11
- 230000036541 health Effects 0.000 description 8
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 7
- 229950006238 nadide Drugs 0.000 description 7
- 230000036039 immunity Effects 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 229920000855 Fucoidan Polymers 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- -1 Lipid Peroxide Chemical class 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BQOHYSXSASDCEA-KEOHHSTQSA-N Cyclic ADP-Ribose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=2N=CN3C(C=2N=C1)=N)O)O)OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]3O1 BQOHYSXSASDCEA-KEOHHSTQSA-N 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 description 1
- 230000035045 associative learning Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000012074 hearing test Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种改善记忆力、延缓衰老、抗氧化的片剂及其制备方法，该片剂包括以下重量份组份：NMN 100‑400、海带提取物50‑200、硒0.01‑0.1、锌1‑9、微晶纤维素50‑200、淀粉50‑600、乳糖10‑100、硬脂酸镁5‑50、二氧化硅10‑100、香精5‑50以及包衣预混剂适量。本发明的改善记忆力、延缓衰老、抗氧化的片剂，复合后各组份不仅发挥了其自身的功效，同时协同增效，将自身的效果放大满足越来越多人群的需要；制备方法简单；片剂口服更加方便，便于携带，同时尚未发现其与已知的药物相互作用，可以长期安全用药，满足多种人群的需要。
Description
技术领域
本发明涉及食品及医药技术领域，特别涉及一种改善记忆力、延缓衰老、抗氧化的片剂及其制备方法。
背景技术
人体衰老过程中的生理变化主要体现在机体组织细胞和构成物质的丧失，机体代谢率的减缓，机体和器官功能减退。衰老是不可避免的，但延缓衰老却是可能的。衰老的特点是1)有时间的依赖性。2)是生物体内所有细胞、组织、器官和整体普遍存在的现象。3)是由自然趋势所造成的内生性变化。可以说人从一出生就开始衰老，但是只有达到一定年龄的蓄积之后衰老的特征才会显现出来。目前抗衰老的机制有很多，主要包括增强细胞活力、清除氧自由基、增强免疫力等方面发挥作用。
NAD+是三羧酸循环的重要辅酶，促进糖、脂肪、氨基酸的代谢，参与能量的合成；NAD+又是辅酶I消耗酶的唯一底物(DNA修复酶PARP的唯一底物、长寿蛋白Sirtuins的唯一底物、环ADP核糖合成酶CD38/157的唯一底物)。简单地说NAD+是细胞能量转化的重要辅酶，其会随着年龄增长减少，而NAD浓度下降后可能导致神经衰退、视力下降、肥胖、心脏功能衰退等多种人体功能下降，因此提出提高人体内的NAD浓度被认为具有抗衰老的功能。
氧在代谢过程中可以产生多种性质活泼的自由基，这些自由基使生物膜的多元不饱和脂肪酸发生脂质过氧化，生成脂质过氧化物(LPO)，LPO可分解产生丙二醛(MDA)，MDA是一种有害物质，它可引起多种生化毒性反应，形成老年斑、脂褐素等异常代谢产物，造成机体衰老和多种疾病。人体内存在抗氧化系统，超氧化物歧化酶(SOD)，过氧化氢酶(CAT)和谷胱甘肽过氧化物酶(GSH-Px)均能消除体内自由基，减少其对机体的损伤。
有关衰老的研究表明，细胞免疫功能低下是导致衰老及多种老年性疾病的重要原因之一。而许多免疫增强活性物质均具有抗衰老作用。
β-烟酰胺单核苷酸(简称NMN)是目前已知的提高体内NAD+浓度作用最直接最迅速的前体物质，相比其他例如Nic(烟酰胺)、Try(色氨酸)、 NR(烟酰胺核糖)等合成途径不确定，NMN的合成途径以及相关反应步骤均明确，且NMN目前在动物和人体实验中证实其安全性较高。近年来， Science、Nature、Cell等期刊刊登了多篇NMN功效研究的文章，哈佛大学实验更是证实补充NMN可将哺乳动物寿命延长30％以上，因此，NMN倍受保健品药品市场的追捧。但是目前NMN市场价格偏高，每公斤价格近万元，进口制品价格更高，无法使普通百姓真正获益。
海带提取物中主要功效成分为褐藻多糖硫酸酯也叫褐藻糖胶，是一种多糖类物质。研究表明，褐藻多糖硫酸酯，具有抗氧化、抗衰老、抗肿瘤、抗辐射、抗血栓、降血糖血脂等多种作用。许多海藻多糖可通过增强SOD，CAT 和GSH-Px等抗氧化剂的活性，加速自由基的消除，减少LPO，MDA及脂褐素的含量，而具有抗衰老的作用。硒是人体必需的微量元素之一，硒可提高机体免疫力，被称为“抗癌之王”；同时，硒有较强的抗氧化作用，它能清除自由基，具有很好的抗衰老功效。
锌也是人体必需的微量元素之一，在人体生长发育过程中其可维持中枢神经系统代谢、骨骼代谢，保障、促进儿童体格(如身高、体重等)生长、大脑发育、性征发育及性成熟的正常进行。同时锌还具有提高免疫功能，增强对疾病的抵抗力。锌是对免疫力影响最明显的微量元素，除直接促进胸腺、淋巴结等免疫器官发育、行使功能外，还有直接抗击某些细菌、病毒的能力，从而减少患病的机会。
目前，人们对生活质量的要求越来越高，生命不仅要有高度还要有宽度，也就是说不仅要长寿，同样生活还要有质量。因此，各种营养品、保健品应运而生。然而，现有的保健品往往功能单一，这就造成了人们在选择保健品的时候要选择多款保健品，使用的时候也是多种保健品一起使用，长此以往很容易造成保健品中个别元素超标甚至中毒，影响生命安全。本发明根据衰老机理不同，巧妙的将NMN、海带提取物以及锌、硒进行搭配，研制了改善记忆力、延缓衰老、抗氧化的片剂，其在保证生活质量不降低的情况下延长人的寿命。
发明内容
本发明所要解决的技术问题是提供一种改善记忆力、延缓衰老、抗氧化的片剂及其制备方法，其克服了现有产品功效单一的缺点，并结合不同的抗衰老机制发挥功效，可以适用于多种人群，安全无毒，使用效果好。
本发明所要解决的技术问题是通过以下技术方案来实现的：一种改善记忆力、延缓衰老、抗氧化的片剂，包括以下重量份组份：NMN 100-400、海带提取物50-200、硒0.01-0.1、锌1-9、微晶纤维素50-200、淀粉50-600、乳糖10-100、硬脂酸镁5-50、二氧化硅10-100、香精5-50以及包衣预混剂适量。
优选地，上述技术方案中，包括以下重量份组份：NMN 200-350、海带提取物100-200、硒0.01-0.05、锌1-5、微晶纤维素75-200、淀粉100-450、乳糖35-75、硬脂酸镁10-40、二氧化硅10-70、香精5-35以及包衣预混剂适量。
优选地，上述技术方案中，包括以下重量份组份：NMN 333.5、海带提取物200、硒0.01、锌1、微晶纤维素130、淀粉240、乳糖55、硬脂酸镁15、二氧化硅10、香精8以及包衣预混剂适量。。
一种改善记忆力、延缓衰老、抗氧化的片剂的制备方法，包括以下步骤：
(1)原料称取：按配方量称取各组份，备用；
(2)将参与制粒的原辅料过80目筛，加入混合机混合均匀，加适量水制粒；
(3)将制好的湿颗粒在40-80℃下干燥20-60min，控制颗粒水分3-5％；
(4)整粒：将干燥好的颗粒过20目筛，整粒；
(5)混合：加入配方量香精、润滑剂混合均匀；
(6)压片：用旋转式压片机进行压片，1.0g/片，定期检查片重差异；
(7)包衣：合格素片进行包衣；
(8)包装：按包装规格进行包装。
优选地，上述技术方案中，所述步骤(3)干燥的温度为60℃，干燥时间为40min。
一种改善记忆力、延缓衰老、抗氧化的片剂在制备具有改善记忆力、延缓衰老、抗氧化的药品或食品中的应用。
NMN，其对人体细胞修复，减缓衰老有重要的作用。因此，NMN倍受保健品药品市场的追捧。但是目前NMN市场价格偏高，所以单独的将NMN 作为保健品使用对于普通消费人群来说显然是奢望。
海带虽然营养价值比较高，但是一般海带是不容易煮烂的，不煮烂的海带不容易消化，尤其对于肠胃不好的人，海带是很难接受的。因此，本申请选取海带提取物，将不容易消化吸收的海带以提取物的形式加入配方，其在保留其自身的抗癌作用、抗氧化作用、抗诱变性作用的同时，有能满足特殊人群的需要。海带配以NMN，不仅降低了配方中NMN的成本，同时通过实验表明海带和NMN组合物的抗癌和抗氧化效果都较单独的食用海带的效果更优。
硒具有抗癌、抗氧化作用，同时也具有抗衰老作用，硒和海带的结合，使得海带的抗癌效果得以提升的同时又补充了人体所需的硒元素。锌可以保证人体大脑、神经的发育，提升免疫系统的功能，缺锌会出现发育受阻、厌食，免疫力下降等一些列症状，而海带虽然营养丰富，但是海带中却是不含锌的，所以我们巧妙的将锌和海带结合起来，一方面利用锌提高免疫力和身体机能，另一方面锌的加入使得片剂的功能更加多元化。
本发明上述技术方案，具有如下有益效果：
(1)本申请制备得到的片剂，复合后各组份不仅发挥了其自身的功效，同时协同增效，将自身的效果放大满足越来越多人群的需要。
(2)申请的片剂的制备方法简单，制备得到的片剂不仅能够改善记忆力、延缓衰老，同时还能抗氧化、抗癌的功效；
(3)本申请制备得到的片剂口服更加方便，便于携带，同时尚未发现其与已知的药物相互作用，可以长期安全用药，满足多种人群的需要。
具体实施方式
下面对本发明的具体实施例进行详细描述，以便于进一步理解本发明。以下实施例中所有使用的实验方法如无特殊说明，均为常规方法。以下实施例中所用的材料、试剂等，如无特殊说明，均可通过商业途径获得。
实施例1
一种改善记忆力、延缓衰老、抗氧化的片剂，包括以下组份(g)：NMN 100、海带提取物200、硒0.01、锌9、微晶纤维素150、淀粉410、乳糖10、硬脂酸镁50、二氧化硅10、香精50以及包衣预混剂适量。
上述改善记忆力、延缓衰老、抗氧化的咀嚼片的制备方法，包括以下步骤：
(1)原料称取：按配方量称取各组份，备用；
(2)将参与制粒的原辅料过80目筛，加入混合机混合均匀，加适量水制粒；
(3)将制好的湿颗粒在40℃下干燥60min，控制颗粒水分4％；
(4)整粒：将干燥好的颗粒过20目筛，整粒；
(5)混合：加入配方量香精、润滑剂混合均匀；
(6)压片：用旋转式压片机进行压片，1.0g/片，定期检查片重差异；
(7)包衣：合格素片进行包衣；
(8)包装：按包装规格进行包装。
实施例2
一种改善记忆力、延缓衰老、抗氧化的片剂，包括以下组份(g)：NMN 400、海带提取物50、硒0.1、锌3、微晶纤维素150、淀粉180、乳糖100、硬脂酸镁5、二氧化硅100、香精5以及包衣预混剂适量。
其制备方法同实施例1，其不同在于步骤(3)的温度为80℃，干燥时间 20min。
实施例3
一种改善记忆力、延缓衰老、抗氧化的片剂，包括以下组份(g)：NMN 200、海带提取物200、硒0.03、锌5、微晶纤维素175、淀粉250、乳糖75、硬脂酸镁40、二氧化硅10、香精35以及包衣预混剂适量。
其制备方法同实施例1，其不同在于步骤(3)的温度为60℃，干燥时间 40min。
实施例4
一种改善记忆力、延缓衰老、抗氧化的片剂，包括以下组份(g)：NMN 350、海带提取物100、硒0.07、锌1、微晶纤维素140、淀粉280、乳糖35、硬脂酸镁10、二氧化硅70、香精5以及包衣预混剂适量。
其制备方法同实施例3。
实施例5
一种改善记忆力、延缓衰老、抗氧化的片剂，包括以下组份(g)：NMN 333.5、海带提取物200、硒0.01、锌1、微晶纤维素130、淀粉240、乳糖55、硬脂酸镁15、二氧化硅10、香精8以及包衣预混剂适量。
其制备方法同实施例3。
对实施例1-5的产品的压片过程会否存在粘冲现象进行考察，发现5款产品均未出现粘冲现象。也就是说，本申请生产的产品能够满足生产和使用的要求。
对实施例1-5的产品进行效果评测：
(1)抗氧化能力：
对实施例1-5的5款产品进行抗氧化能力检测，结果如表1所示。
表1抗氧化能力表
| 对羟自由基的清除能力(％) | 超氧阴离子自由基清除能力(％) | |
| 实施例1 | 70 | 70 |
| 实施例2 | 80 | 75 |
| 实施例3 | 85 | 80 |
| 实施例4 | 89 | 82 |
| 实施例5 | 91 | 85 |
结果表明，本申请的实施例1-5咀嚼片剂具有对羟自由基的清除能力和超氧阴离子自由基清除能力。尤其是实施例5，其对两个自有的效果均最强。
(2)改善记忆力
对实施例1-5的5款产品进行记忆力测试，结果如表2所示。
表2对小鼠水迷宫实验记忆获得的影响
结果表明，本申请的实施例1-5片剂对改善记忆力效果明显，小鼠能够在较短的时间内登上救生台，且登上救生台动物次数的百分率和登上救生台动物百分率较对照组大幅度提升。
(3)临床效果：
将实施例1-5制备得到的片剂进行以下人体试食实验(实施例1-5的份数量即为1片片剂的含量)：
(1)选择符合要求的自愿受试者300人(对照组和实施例组(1-5)每组各50人)进行受试实验。
对照组服用安慰剂(不含有效成分，但剂型、色泽、外观、口感、包装等均与受试样一致)已消除心理暗示的影响。同一受试者先后进行两次测试由同一个主试者进行，施测顺序为先是听觉测试后视觉测试。具体测序顺序是(1)指向记忆、(2)联想学习、(3)无意义图形再认、(4)图像自由回忆、(5)人像特点联系回忆。
(2)将受试者进行分组受试，试食组按推荐服用方法、服用量服用受试产品，对照组服用安慰剂(空白对照)。按双盲法进行试食试验。样品给与时间30天。
食用方法：每日3次，每次2片。
(3)观察受试者指标，主要包括安全指标和功效指标：
安全指标包括精神、睡眠、饮食、心率等；检查血尿便等常规项目；检查肝肾功能；检查胸、心电图以及腹部B超等；
功效指标：使用临床记忆量表。用测试后的各分测验原始分查量表分，各分测验量表分相加得总分量表，用总分量表查记忆商，结果见表3。
表3记忆商量表
对300例受试者进行跟踪观察，对实施例1-5的治疗效果进行对比发现，用临床记忆量表法进行的人体试食试验结果表明,实施例1-5的效果明显优于对照组，尤其是实施例5受试者连续服用该保健食品30d(6g/d)以后，记忆商(MQ)有显著提高，且与对照组比差异有极显著性。
将上述制备方法制备得到的片剂应用于制备具有改善记忆力、延缓衰老、抗氧化的药品或食品中，该食品或药品具有明显改善记忆力、延缓衰老以及抗氧化性。
虽然本发明已以实施例公开如上，然其并非用于限定本发明，任何本领域技术人员，在不脱离本发明的精神和范围内，均可作各种不同的选择和修改，因此本发明的保护范围由权利要求书及其等同形式所限定。
Claims (6)
1.一种改善记忆力、延缓衰老、抗氧化的片剂，其特征在于，包括以下重量份组份：NMN100-400、海带提取物50-200、硒0.01-0.1、锌1-9、微晶纤维素50-200、淀粉50-600、乳糖10-100、硬脂酸镁5-50、二氧化硅10-100、香精5-50以及包衣预混剂适量。
2.根据权利要求1所述的改善记忆力、延缓衰老、抗氧化的片剂，其特征在于，包括以下重量份组份：NMN 200-350、海带提取物100-200、硒0.01-0.05、锌1-5、微晶纤维素75-200、淀粉100-450、乳糖35-75、硬脂酸镁10-40、二氧化硅10-70、香精5-35以及包衣预混剂适量。
3.根据权利要求2所述的改善记忆力、延缓衰老、抗氧化的片剂，其特征在于，包括以下重量份组份：NMN 333.5、海带提取物200、硒0.01、锌1、微晶纤维素130、淀粉240、乳糖55、硬脂酸镁15、二氧化硅10、香精8以及包衣预混剂适量。
4.根据权利要求1-3任一所述的改善记忆力、延缓衰老、抗氧化的片剂的制备方法，其特征在于，包括以下步骤：
(1)原料称取：按配方量称取各组份，备用；
(2)将参与制粒的原辅料过80目筛，加入混合机混合均匀，加适量水制粒；
(3)将制好的湿颗粒在40-80℃下干燥20-60min，控制颗粒水分3-5％；
(4)整粒：将干燥好的颗粒过20目筛，整粒；
(5)混合：加入配方量香精、润滑剂混合均匀；
(6)压片：用旋转式压片机进行压片，1.0g/片，定期检查片重差异；
(7)包衣：合格素片进行包衣；
(8)包装：按包装规格进行包装。
5.根据权利要求4所述的改善记忆力、延缓衰老、抗氧化的片剂的制备方法，其特征在于，所述步骤(3)干燥的温度为60℃，干燥时间为40min。
6.根据权利要求4-5任一所述制备方法制备的片剂在制备具有改善记忆力、延缓衰老、抗氧化的药品或食品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010991627.3A CN112190601A (zh) | 2020-09-18 | 2020-09-18 | 一种改善记忆力、延缓衰老、抗氧化的片剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010991627.3A CN112190601A (zh) | 2020-09-18 | 2020-09-18 | 一种改善记忆力、延缓衰老、抗氧化的片剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112190601A true CN112190601A (zh) | 2021-01-08 |
Family
ID=74015687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010991627.3A Pending CN112190601A (zh) | 2020-09-18 | 2020-09-18 | 一种改善记忆力、延缓衰老、抗氧化的片剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112190601A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113133981A (zh) * | 2021-04-20 | 2021-07-20 | 北京天玺宝科技有限公司 | β-烟酰胺单核苷酸口崩片及其制备方法 |
| CN116420877A (zh) * | 2022-08-11 | 2023-07-14 | 郭志福 | Nmn、钾、镁、硒组合物营养片及制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
| CN111093397A (zh) * | 2017-09-14 | 2020-05-01 | 田中惠 | 一种抗衰老剂以及抗衰老方法 |
-
2020
- 2020-09-18 CN CN202010991627.3A patent/CN112190601A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
| CN111093397A (zh) * | 2017-09-14 | 2020-05-01 | 田中惠 | 一种抗衰老剂以及抗衰老方法 |
Non-Patent Citations (1)
| Title |
|---|
| 李云捷等: "《食品营养学》", 30 September 2018, 西南交通大学出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113133981A (zh) * | 2021-04-20 | 2021-07-20 | 北京天玺宝科技有限公司 | β-烟酰胺单核苷酸口崩片及其制备方法 |
| CN116420877A (zh) * | 2022-08-11 | 2023-07-14 | 郭志福 | Nmn、钾、镁、硒组合物营养片及制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9226911B2 (en) | Method of reducing weight using composition containing fucoxanthin extract | |
| CN102813115A (zh) | 复方活性美容胶原蛋白粉 | |
| CN104432037B (zh) | 抗氧化的保健营养组合物及其制备方法与应用 | |
| CN112206237A (zh) | 一种含有牛磺酸锌的抗衰老组合物、制备方法及其应用 | |
| CN102144748A (zh) | 具有排毒护肝养颜功能的五色面制食品 | |
| Babich et al. | In vivo study of the potential of the carbohydrate-mineral complex from pine nut shells as an ingredient of functional food products | |
| CN112190601A (zh) | 一种改善记忆力、延缓衰老、抗氧化的片剂及其制备方法 | |
| CN102753183A (zh) | 运动功能改善剂 | |
| CN107455625A (zh) | 一种具有抗疲劳减肥功能的植物营养素饮料及其制备工艺 | |
| Mironenko et al. | Vitamin B9–description, benefits, effects on the body and best sources | |
| CN101428037A (zh) | 含修复因子的抗衰老组合物 | |
| CN108635258B (zh) | 一种高效抗氧化的富硒植物酵素原液及其制备和应用 | |
| CN113855735A (zh) | 一种促进代谢消化的组合物及其制备方法 | |
| CN106661542A (zh) | 新型乳酸菌和包含所述乳酸菌的组合物 | |
| CN102090453A (zh) | 瘦身美奶茶 | |
| CN102090637A (zh) | 一种含有胶原蛋白的复方营养粉 | |
| RU2390271C1 (ru) | Средство для повышения адаптируемости организма к экстремальным условиям | |
| CN107439866A (zh) | 枸杞鹰嘴豆植物营养素饮料及其制备工艺 | |
| CN106942561A (zh) | 一种饮料组合物及其制备方法与应用 | |
| CN109157548B (zh) | 一种具有抗疲劳和壮阳功能的组合物及制备方法 | |
| CN106819223A (zh) | 一种保健奶茶及其制备方法 | |
| Dubick | Dietary supplements and health aids—A critical evaluation part 3—Natural and miscellaneous products | |
| CN105192698B (zh) | 一种含有辣木叶粉的保健食品及其制备方法 | |
| AU2021101163A4 (en) | An algal oil DHA drop agent and its preparation method | |
| RU2781249C1 (ru) | Специализированный пищевой продукт для диетического лечебного и диетического профилактического питания детей старше трех лет и способ его применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 11F-1, 11th Floor, Block B, No. 3 Shilibaojia, Chaoyang District, Beijing 100025 Applicant after: Beijing Jianxun Pharmaceutical Technology Co.,Ltd. Address before: 1812, block B, Jinhai business center, Baiziwan, Chaoyang District, Beijing Applicant before: Beijing Jianxun Pharmaceutical Technology Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210108 |